Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice

References

• Fiorino G, Allocca M, Danese S. Anemia in inflammatory bowel disease: the opening of pandora’s box?. Clin Gastroenterol Hepatol. 2015;13:1767–1769.
   PubMed Web of Science ®Google Scholar
• Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010;42:97–114.
   PubMed Web of Science ®Google Scholar
• Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey. Eur J Gastroenterol Hepatol. 2014;26:1385–1391.
   PubMed Web of Science ®Google Scholar
• Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol. 2013;25:1456–1463.
   PubMed Web of Science ®Google Scholar
• Blumenstein I, Dignass A, Vollmer S, et al. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis. 2014;8:1308–1314.
   PubMed Web of Science ®Google Scholar
• Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol. 2011;46:304–309.
   PubMed Web of Science ®Google Scholar
• Voegtlin M, Vavricka SR, Schoepfer AM, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis. 2010;4:642–648.
   PubMed Web of Science ®Google Scholar
• Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scand J Gastroenterol. 2013;48:1286–1293.
   PubMed Web of Science ®Google Scholar
• Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:513–519.
   PubMed Web of Science ®Google Scholar
• Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol. 2015;13:308–318.
   PubMedGoogle Scholar
• Rejler M, Tholstrup J, Andersson-Gare B, et al. Low prevalence of anemia in inflammatory bowel disease: a population-based study in Sweden. Scand J Gastroenterol. 2012;47:937–942.
   PubMed Web of Science ®Google Scholar
• Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol. 2013;26:104–113.
   PubMedGoogle Scholar
• Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629–638.
   PubMed Web of Science ®Google Scholar
• Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–130.
   PubMed Web of Science ®Google Scholar
• Lopez A, Cacoub P, Macdougall IC, et al. Iron deficiency anaemia. The Lancet. 2016;387:907–916.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.
   PubMed Web of Science ®Google Scholar
• Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
   PubMed Web of Science ®Google Scholar
• Walker AM, Szneke P, Bianchi LA, et al. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997;92:816–820.
   PubMed Web of Science ®Google Scholar
• Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429–436.
   PubMedGoogle Scholar
• Blanchet E, Beau P, Frat JP. [Bone marrow aplasia following dipyrone treatment in a patient with Crohn’s disease receiving long-term methotrexate]. Gastroenterol Clin Biol. 2004;28:502–503.
   PubMedGoogle Scholar
• Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. 2004;36:703–704.
   PubMed Web of Science ®Google Scholar
• Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45–51.
   PubMed Web of Science ®Google Scholar
• Sharma N, Begum J, Eksteen B, et al. Differential ferritin expression is associated with iron deficiency in coeliac disease. Eur J Gastroenterol Hepatol. 2009;21:794–804.
   PubMed Web of Science ®Google Scholar
• Johnson D, Bayele H, Johnston K, et al. Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett. 2004;573:195–201.
   PubMed Web of Science ®Google Scholar
• Cartwright GE, Lauritsen MA, Humphreys S, et al. The anemia associated with chronic infection. Science. 1946;103:72–73.
   Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28: 671–681. vi.
   PubMed Web of Science ®Google Scholar
• Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? Cmaj. 2008;179:333–337.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.
   PubMed Web of Science ®Google Scholar
• Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol. 2013;9:205–215.
   PubMed Web of Science ®Google Scholar
• Stein J, Stier C, Raab H, et al. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40:582–609.
   PubMed Web of Science ®Google Scholar
• Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab. Hematol. 2005;11(1):14–23.
   PubMedGoogle Scholar
• Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis. 2013;7:9–22.
   PubMed Web of Science ®Google Scholar
• Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1 Suppl 1:S4–8.
   PubMed Web of Science ®Google Scholar
• Martin J, Radeke HH, Dignass A, et al. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11:19–32.
   PubMed Web of Science ®Google Scholar
• Heimpel H, Diem H, Nebe T. Counting reticulocytes: new importance of an old method. Med Klin (Munich). 2010;105:538–543.
   PubMedGoogle Scholar
• Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor, ferritin and TfR-F index in identification of latent iron deficiency. Eur J Haematol. 1998;60:135–137.
   PubMed Web of Science ®Google Scholar
• Harms K, Kaiser T. Beyond soluble transferrin receptor: old challenges and new horizons. Best Pract Res Clin Endocrinol Metab. 2015;29:799–810.
   PubMed Web of Science ®Google Scholar
• Junca J, Fernandez-Aviles F, Oriol A, et al. The usefulness of the serum transferrin receptor in detecting iron deficiency in the anemia of chronic disorders. Haematologica. 1998;83:676–680.
   PubMed Web of Science ®Google Scholar
• Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86:923–927.
   PubMed Web of Science ®Google Scholar
• Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol. 2011;24:108–114.
   PubMedGoogle Scholar
• Abitbol V, Borderie D, Polin V, et al. Diagnosis of iron deficiency in inflammatory bowel disease by transferrin receptor-ferritin index. Medicine (Baltimore). 2015;94:e1011.
   PubMed Web of Science ®Google Scholar
• Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes’s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222–230.
   PubMed Web of Science ®Google Scholar
• Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med. 2012;50:685–687.
   Web of Science ®Google Scholar
• Parodi E, Giraudo MT, Davitto M, et al. Reticulocyte parameters: markers of early response to oral treatment in children with severe iron-deficiency anemia. J Pediatr Hematol Oncol. 2012;34:e249–52.
   PubMed Web of Science ®Google Scholar
• Dagg JH, Goldberg A, Lochhead A. Value of erythrocyte protoporphyrin in the diagnosis of latent iron deficiency (sideropenia). Br J Haematol. 1966;12:326–330.
   PubMed Web of Science ®Google Scholar
• Hastka J, Lasserre JJ, Schwarzbeck A, et al. Zinc protoporphyrin in anemia of chronic disorders. Blood. 1993;81:1200–1204.
   PubMed Web of Science ®Google Scholar
• Wiesenthal M, Dienethal A, Dignass AU, et al. Diagnostic accuracy of zinc protoporphyrin/heme ratio for screening of iron deficiency anaemia in patients with inflammatory bowel disease. Gastroenterology. 2014;146:S599–S599.
   PubMed Web of Science ®Google Scholar
• Akkermans MD, Vreugdenhil M, Hendriks DM, et al. Iron deficiency in inflammatory bowel disease: the use of zincprotoporphyrin and red blood cell distribution width. J Pediatr Gastroenterol Nutr. 2017;64(6):949–954.
   PubMed Web of Science ®Google Scholar
• Wiesenthal M, Dignass A, Hartmann F, et al. Serum hepcidin levels predict intestinal iron absorption in IBD patients. J Crohns Colitis. 2014;8:S120–S120.
   PubMed Web of Science ®Google Scholar
• Martinelli M, Strisciuglio C, Alessandrella A, et al. Serum hepcidin and iron absorption in paediatric inflammatory bowel disease. J Crohns Colitis. 2016;10:566–574.
   PubMed Web of Science ®Google Scholar
• Forbes A, Escher J, Hebuterne X, et al. ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017;36:321–347.
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.
   PubMed Web of Science ®Google Scholar
• Tay HS, Soiza RL. Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging. 2015;32:149–158.
   PubMed Web of Science ®Google Scholar
• Rampton DS, Goodhand JR, Joshi NM, et al. Oral iron treatment response and predictors in anaemic adolescents and adults with IBD: a prospective controlled open-label trial. J Crohns Colitis. 2017;11:706–715.
   PubMed Web of Science ®Google Scholar
• Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832–1843.
   PubMed Web of Science ®Google Scholar
• Kortman GA, Raffatellu M, Swinkels DW, et al. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev. 2014;38:1202–1234.
   PubMed Web of Science ®Google Scholar
• De Silva AD, Tsironi E, Feakins RM, et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22:1097–1105.
   PubMed Web of Science ®Google Scholar
• Erichsen K, Ulvik RJ, Grimstad T, et al. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:831–838.
   PubMed Web of Science ®Google Scholar
• Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503–2509.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15:1485–1491.
   PubMed Web of Science ®Google Scholar
• Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr. 2010;92:1406–1415.
   PubMed Web of Science ®Google Scholar
• Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731–742.
   PubMed Web of Science ®Google Scholar
• Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol (N Y). 2015;11:241–250.
   PubMedGoogle Scholar
• Hutchinson C, Al-Ashgar W, Liu DY, et al. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest. 2004;34:782–784.
   PubMed Web of Science ®Google Scholar
• Dresow B, Petersen D, Fischer R, et al. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals. 2008;21:273–276.
   PubMed Web of Science ®Google Scholar
• Brissot P, Ropert M, Le Lan C, et al. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820:403–410.
   PubMed Web of Science ®Google Scholar
• Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3:12–33.
   PubMedGoogle Scholar
• Kaltwasser JP, Hansen C, Oebike Y, et al. Assessment of iron availability using stable 54Fe. Eur J Clin Invest. 1991;21:436–442.
   PubMed Web of Science ®Google Scholar
• Schumann K, Solomons NW, Romero-Abal ME, et al. Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men. Food Nutr Bull. 2012;33:128–136.
   PubMed Web of Science ®Google Scholar
• Schumann K, Solomons NW, Orozco M, et al. Differences in circulating non-transferrin-bound iron after oral administration of ferrous sulfate, sodium iron EDTA, or iron polymaltose in women with marginal iron stores. Food Nutr Bull. 2013;34:185–193.
   PubMed Web of Science ®Google Scholar
• Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Sci World J. 2012;2012:846824.
   Web of Science ®Google Scholar
• Stallmach A, Buning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16:2859–2867.
   PubMed Web of Science ®Google Scholar
• Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998;12:845–848.
   PubMed Web of Science ®Google Scholar
• Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–588.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther. 2016;44:259–270.
   PubMed Web of Science ®Google Scholar
• Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015;30:645–652.
   PubMed Web of Science ®Google Scholar
• Mafodda A, Giuffrida D, Prestifilippo A, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017.
   PubMed Web of Science ®Google Scholar
• Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–1989.
   PubMed Web of Science ®Google Scholar
• Powell JJ, Cook WB, Hutchinson C, et al. Dietary fortificant iron intake is negatively associated with quality of life in patients with mildly active inflammatory bowel disease. Nutr Metab (Lond). 2013;10:9.
   PubMed Web of Science ®Google Scholar
• Okam MM, Koch TA, Tran MH. Iron supplementation, response in iron-deficiency anemia: analysis of five trials. Am J Med. 2017;130:991e1–991 e8.
   Web of Science ®Google Scholar
• Avni T, Bieber A, Steinmetz T, et al. Treatment of anemia in inflammatory bowel disease–systematic review and meta-analysis. PLoS One. 2013;8:e75540.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308.
   PubMed Web of Science ®Google Scholar
• Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6:267–275.
   PubMed Web of Science ®Google Scholar
• Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51–60.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475–2491.
   PubMed Web of Science ®Google Scholar
• Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992;42:1439–1452.
   PubMed Web of Science ®Google Scholar
• Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities]. Schweiz Med Wochenschr. 1970;100:301–303.
   PubMedGoogle Scholar
• Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-853 e1-2.
   PubMed Web of Science ®Google Scholar
• Schroder O, Schrott M, Blumenstein I, et al. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol. 2004;42:663–667.
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460–1467.
   PubMed Web of Science ®Google Scholar
• Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269–277.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–1233.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–382.
   PubMed Web of Science ®Google Scholar
• Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol. 2013;2013:703038.
   PubMedGoogle Scholar
• Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. Jama. 2015;314:2062–2068.
   PubMed Web of Science ®Google Scholar
• Hussain I, Bhoyroo J, Butcher A, et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013;2013:169107.
   PubMedGoogle Scholar
• Charytan C, Schwenk MH, Al-Saloum MM, et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004;96:c63–6.
   PubMedGoogle Scholar
• Lee ES, Park BR, Kim JS, et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin. 2013;29:141–147.
   PubMed Web of Science ®Google Scholar
• Rottembourg J, Kadri A, Leonard E, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant. 2011;26:3262–3267.
   PubMed Web of Science ®Google Scholar
• Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin. 2012;28:241–243.
   PubMed Web of Science ®Google Scholar
• Li X, Kshirsagar AV, Brookhart MA. Safety of intravenous iron in hemodialysis patients. Hemodial Int. 2017;21 Suppl 1:S93–S103.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015;172:5025–5036.
   PubMed Web of Science ®Google Scholar
• Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671–1676.
   PubMed Web of Science ®Google Scholar
• Hempel JC, Poppelaars F, Gaya Da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45:49–59.
   PubMed Web of Science ®Google Scholar
• (EMA). Assessment report for: iron containing intravenous (IV) medicinal products. [cited 2017 Apr 23]. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf 2013.
   Google Scholar
• Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266–275.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Wurtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One. 2016;11:e0167146.
   PubMed Web of Science ®Google Scholar
• Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266–275.
   PubMed Web of Science ®Google Scholar
• Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.
   PubMed Web of Science ®Google Scholar
• Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108:E1146–55.
   PubMed Web of Science ®Google Scholar
• Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60:655–661.
   PubMed Web of Science ®Google Scholar
• Goldsweig BK, Carpenter TO. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Curr Osteoporos Rep. 2015;13:88–97.
   PubMed Web of Science ®Google Scholar
• O’Connor LR, Wheeler WS, Bethune JE. Effect of hypophosphatemia on myocardial performance in man. N Engl J Med. 1977;297:901–903.
   PubMed Web of Science ®Google Scholar
• Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14:R147.
   PubMed Web of Science ®Google Scholar
• National cancer institute common terminology criteria for adverse events v4.0 NCI, NIH, DHHS. NIH. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21 Suppl 1:S83–s92.
   PubMed Web of Science ®Google Scholar
• Schroeder SE, Reddy MB, Schalinske KL. Retinoic acid modulates hepatic iron homeostasis in rats by attenuating the RNA-binding activity of iron regulatory proteins. J Nutr. 2007;137:2686–2690.
   PubMed Web of Science ®Google Scholar
• Aksan A, Isik H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–1318.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–3080.
   PubMed Web of Science ®Google Scholar
• Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–1632.
   PubMed Web of Science ®Google Scholar
• Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol. 2013;88:990–996.
   PubMed Web of Science ®Google Scholar
• Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011;7:501–509.
   PubMed Web of Science ®Google Scholar
• Calvet X, Ruiz MA, Dosal A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One. 2012;7:e45604.
   PubMed Web of Science ®Google Scholar
• Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis. 2010;4:427–430.
   PubMed Web of Science ®Google Scholar
• Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol. 2007;13:4798–4806.
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler DOV, Iaina A, et al. Anemia, chronic renal disease and chronic heart failure: the cardiorenal anemia syndrome. Transfus Alternatives Transfus Med. 2008;10:189–196.
   Google Scholar
• Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–2552.
   PubMed Web of Science ®Google Scholar
• Mehra T, Seifert B, Bravo-Reiter S, et al. Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. Transfusion. 2015;55:2807–2815.
   PubMed Web of Science ®Google Scholar
• Eliadou E, Kini G, Huang J, et al. Intravenous iron replacement improves quality of life in hypoferritinemic inflammatory bowel disease patients with and without anemia. Dig Dis. 2017.
   PubMed Web of Science ®Google Scholar
• Cekic C, Ipek S, Aslan F, et al. The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterol Res Pract. 2015;2015:582163.
   PubMed Web of Science ®Google Scholar